Epigallocatechin‐3‐gallate sensitises multidrug‐resistant oral carcinoma xenografts to vincristine sulfate
Oral squamous cell carcinoma (OSCC) is a very aggressive malignancy, and 50% of patients who receive curative treatment die from the disease or related complications within 5 years. Epigallocatechin‐3‐gallate (EGCG) is the most abundant bioactive ingredient of tea polyphenols in green tea and has an...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2020-07-01
|
| Series: | FEBS Open Bio |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/2211-5463.12905 |
| _version_ | 1797821927918665728 |
|---|---|
| author | Li Chen Xianwen Guo Ye Hu Li Li Gang Liang Guo Zhang |
| author_facet | Li Chen Xianwen Guo Ye Hu Li Li Gang Liang Guo Zhang |
| author_sort | Li Chen |
| collection | DOAJ |
| description | Oral squamous cell carcinoma (OSCC) is a very aggressive malignancy, and 50% of patients who receive curative treatment die from the disease or related complications within 5 years. Epigallocatechin‐3‐gallate (EGCG) is the most abundant bioactive ingredient of tea polyphenols in green tea and has anticancer properties. Here, we evaluated the preclinical efficacy of EGCG combined with vincristine sulfate (VCR) on the growth, angiogenic activity and vascular endothelial growth factor (VEGF) expression in xenograft nude mice inoculated with KBV200 cells. Compared with VCR alone, the combined use of EGCG and VCR strongly inhibited tumour growth and angiogenesis (P < 0.01). VEGF mRNA and protein levels were lower in the KBV200 xenograft group treated with the combined regime (P < 0.01) than those in the VCR alone group. EGCG sensitises multidrug‐resistant OSCC to VCR, and this may occur through the inhibition of angiogenesis via VEGF down‐regulation. |
| first_indexed | 2024-03-13T09:59:55Z |
| format | Article |
| id | doaj.art-94b0c0ccfed048f3834c5113697c5688 |
| institution | Directory Open Access Journal |
| issn | 2211-5463 |
| language | English |
| last_indexed | 2024-03-13T09:59:55Z |
| publishDate | 2020-07-01 |
| publisher | Wiley |
| record_format | Article |
| series | FEBS Open Bio |
| spelling | doaj.art-94b0c0ccfed048f3834c5113697c56882023-05-23T06:51:08ZengWileyFEBS Open Bio2211-54632020-07-011071403141310.1002/2211-5463.12905Epigallocatechin‐3‐gallate sensitises multidrug‐resistant oral carcinoma xenografts to vincristine sulfateLi Chen0Xianwen Guo1Ye Hu2Li Li3Gang Liang4Guo Zhang5New Drug Research & Development Center First Affiliated Hospital of Guangxi Medical University Nanning ChinaDepartment of Gastroenterology The People's Hospital of Guangxi Zhuang Autonomous Region Nanning ChinaDepartment of Gastroenterology The People's Hospital of Guangxi Zhuang Autonomous Region Nanning ChinaPharmacy School of Guangxi Medical University Nanning ChinaPharmacy School of Guangxi Medical University Nanning ChinaDepartment of Gastroenterology The People's Hospital of Guangxi Zhuang Autonomous Region Nanning ChinaOral squamous cell carcinoma (OSCC) is a very aggressive malignancy, and 50% of patients who receive curative treatment die from the disease or related complications within 5 years. Epigallocatechin‐3‐gallate (EGCG) is the most abundant bioactive ingredient of tea polyphenols in green tea and has anticancer properties. Here, we evaluated the preclinical efficacy of EGCG combined with vincristine sulfate (VCR) on the growth, angiogenic activity and vascular endothelial growth factor (VEGF) expression in xenograft nude mice inoculated with KBV200 cells. Compared with VCR alone, the combined use of EGCG and VCR strongly inhibited tumour growth and angiogenesis (P < 0.01). VEGF mRNA and protein levels were lower in the KBV200 xenograft group treated with the combined regime (P < 0.01) than those in the VCR alone group. EGCG sensitises multidrug‐resistant OSCC to VCR, and this may occur through the inhibition of angiogenesis via VEGF down‐regulation.https://doi.org/10.1002/2211-5463.12905angiogenesisepigallocatechin‐3‐gallatemultidrug resistanceoral squamous cell carcinomatumour growthvincristine sulfate |
| spellingShingle | Li Chen Xianwen Guo Ye Hu Li Li Gang Liang Guo Zhang Epigallocatechin‐3‐gallate sensitises multidrug‐resistant oral carcinoma xenografts to vincristine sulfate FEBS Open Bio angiogenesis epigallocatechin‐3‐gallate multidrug resistance oral squamous cell carcinoma tumour growth vincristine sulfate |
| title | Epigallocatechin‐3‐gallate sensitises multidrug‐resistant oral carcinoma xenografts to vincristine sulfate |
| title_full | Epigallocatechin‐3‐gallate sensitises multidrug‐resistant oral carcinoma xenografts to vincristine sulfate |
| title_fullStr | Epigallocatechin‐3‐gallate sensitises multidrug‐resistant oral carcinoma xenografts to vincristine sulfate |
| title_full_unstemmed | Epigallocatechin‐3‐gallate sensitises multidrug‐resistant oral carcinoma xenografts to vincristine sulfate |
| title_short | Epigallocatechin‐3‐gallate sensitises multidrug‐resistant oral carcinoma xenografts to vincristine sulfate |
| title_sort | epigallocatechin 3 gallate sensitises multidrug resistant oral carcinoma xenografts to vincristine sulfate |
| topic | angiogenesis epigallocatechin‐3‐gallate multidrug resistance oral squamous cell carcinoma tumour growth vincristine sulfate |
| url | https://doi.org/10.1002/2211-5463.12905 |
| work_keys_str_mv | AT lichen epigallocatechin3gallatesensitisesmultidrugresistantoralcarcinomaxenograftstovincristinesulfate AT xianwenguo epigallocatechin3gallatesensitisesmultidrugresistantoralcarcinomaxenograftstovincristinesulfate AT yehu epigallocatechin3gallatesensitisesmultidrugresistantoralcarcinomaxenograftstovincristinesulfate AT lili epigallocatechin3gallatesensitisesmultidrugresistantoralcarcinomaxenograftstovincristinesulfate AT gangliang epigallocatechin3gallatesensitisesmultidrugresistantoralcarcinomaxenograftstovincristinesulfate AT guozhang epigallocatechin3gallatesensitisesmultidrugresistantoralcarcinomaxenograftstovincristinesulfate |